Phosphoprotein Stabilization via Permeability Enhancing Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preserving and stabilizing phosphoproteins in clinical specimens are inadequate, as they fail to maintain the phosphorylation state of proteins during the time delay between tissue procurement and molecular analysis, leading to inaccurate molecular data for cancer therapy.
Innovation Solution
A preservative composition that includes a fixative with sufficient water content for stabilizers, such as kinase and phosphatase inhibitors, and a permeability enhancing agent like polyethylene glycol (PEG), which can penetrate cells to rapidly stabilize phosphoproteins at room temperature, preventing metabolic changes and allowing for accurate molecular analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tissue is preserved using conventional methods (formalin fixation or snap-freezing), then histologic examination is preserved, but phosphoprotein phosphorylation state changes during the time delay between procurement and analysis
Solution Approach 1:
The patent applies preliminary action by adding a permeability enhancing agent to the preservative composition before tissue procurement. This agent pre-prepares the tissue by increasing membrane permeability, so that when the preservative is applied, the kinase and phosphatase inhibitors can rapidly penetrate and stabilize phosphoproteins immediately, preventing phosphorylation state changes during the time delay period.
Solution Approach 2:
The patent uses a permeability enhancing agent as an intermediary substance that facilitates the rapid penetration of kinase and phosphatase inhibitors into the tissue. This intermediary overcomes the barrier of cell membranes, allowing the preservative components to reach their targets quickly and stabilize phosphoproteins before metabolic changes can occur during transport and processing.
2Reliability
If tissue is snap-frozen immediately to preserve phosphoproteins, then phosphorylation state is maintained, but immediate refrigeration or freezing is often impossible in busy clinical settings
Solution Approach 1:
The patent applies parameter changes by modifying the physical-chemical parameters of the preservative composition to enable room temperature stabilization. The composition includes kinase and phosphatase inhibitors combined with a permeability enhancing agent, creating a formulation that can rapidly penetrate tissue and stabilize phosphoproteins at room temperature, eliminating the need for immediate freezing while maintaining phosphoprotein stability.
3Shape
If conventional fixatives are used, then tissue morphology is preserved, but phosphoprotein phosphorylation state is not maintained
Solution Approach 1:
The patent uses a composite preservative composition that combines multiple functional components: conventional fixatives for morphology preservation, kinase inhibitors for phosphorylation state maintenance, phosphatase inhibitors to prevent dephosphorylation, and a permeability enhancing agent for rapid penetration. This composite formulation simultaneously achieves both morphology preservation and phosphoprotein stability.
4Reliability
If tissue is processed quickly to minimize time delay, then phosphoprotein stability is improved, but processing speed cannot be controlled in busy clinical settings with variable delays
Solution Approach 1:
The patent employs a disposable preservative composition that can be applied immediately to each tissue sample independently. This allows each sample to be stabilized individually according to its specific processing timeline, regardless of overall clinic throughput. The preservative acts as a self-contained stabilization system that doesn't require coordinated processing of multiple samples, making it adaptable to variable clinical workflows.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively stabilizes phosphoproteins, preserving cellular morphology and enabling accurate molecular analysis, even in the absence of immediate refrigeration, thus facilitating individualized cancer therapy by ensuring reliable molecular data.
Implementation Method 1
a permeability enhancing agent like polyethylene glycol (PEG), which can penetrate cells to rapidly stabilize phosphoproteins
Implementation Method 2
A preservative composition that includes a fixative with sufficient water content for stabilizers, such as kinase and phosphatase inhibitors
Data Source
AI summary
This invention relates, e.g., to a composition that, at room temperature, when contacted with a sample comprising phosphoproteins, can fix and stabilize cellular phosphoproteins, preserve cellular morphology, and allow the sample to be frozen to generate a cryostat frozen section suitable for molecular analysis. The composition comprises (1) a fixative that stabilizes the proteins in the sample and that has a sufficient water content for a stabilizer and/or a permeability enhancing agent to be soluble therein; (2) a stabilizer, comprising (a) a kinase inhibitor and (b) a phosphatase inhibitor and, optionally, (c) a protease (e.g., proteinase) inhibitor; (3) a permeability enhancing agent; and (4) lactic acid. Methods and kits are described for preserving phosphoproteins, using such a composition. Also described are endogenous surrogate markers for monitoring protein degradation, including the loss of posttranslational modifications (such as phosphorylation), e.g. following removal of a cell or tissue from a subject; and exogenous molecular sentinels (e.g. phosphoproteins attached to magnetic nanoparticles) that allow one to evaluate the processing history of a cellular or tissue population sample.